Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BAY 43-9006 inhibition of oncogenic RET mutants.

Journal of the National Cancer Institute - 1 Mar 2006

Carlomagno Francesca, Anaganti Suresh, Guida Teresa, Salvatore Giuliana, Troncone Giancarlo, Wilhelm Scott M, Santoro Massimo

Abstract excerpt

BACKGROUND: Medullary and papillary thyroid carcinomas are often associated with oncogenic activation of the RET tyrosine kinase. We evaluated whether the biaryl urea BAY 43-9006, which is known to inhibit several other tyrosine kinases, blocks RET kinase function and oncogenic activity. METHODS: We examined BAY 43-9006 activity against oncogenic RET in vitro and in cellular RET signaling in oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to NIH 3T3 Cells

Share to Phenylurea Compounds

Share to Phosphotransferases

Share to Sorafenib

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 16507829
DOI: 10.1093/jnci/djj069

Genes

RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BAY 43-9006 inhibition of oncogenic RET mutants.PMID 16507829Read ↗

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Anti-tumor activity of motesanib in a medullary thyroid cancer model.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).Semantic proximity Read ↗

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.Semantic proximity Read ↗

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.Semantic proximity Read ↗

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Semantic proximity Read ↗

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.Semantic proximity Read ↗

Selective RET kinase inhibition for patients with RET-altered cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.